Ocular Therapeutix (OCUL) Cash from Investing Activities (2013 - 2026)
Ocular Therapeutix's quarterly Cash from Investing Activities came in at -$4.7 million in Q1 2026, down 141.18% year-on-year from $11.3 million in Q1 2025, and down 64.21% quarter-over-quarter from -$2.8 million in Q4 2025.
Ocular Therapeutix has reported Cash from Investing Activities for 14 years, with the latest figure at -$4.7 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 141.18% year-over-year to -$4.7 million; the trailing twelve-month figure through Mar 2026 stood at -$14.6 million (down 392.55% YoY), and the FY2025 full-year result was -$11.9 million, down 822.36% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$4.7 million, down from -$2.8 million in the prior quarter.
- The five-year high for Cash from Investing Activities was -$89000.0 in Q3 2024, with the low at -$6.0 million in Q3 2025.
- Average Cash from Investing Activities over 5 years is -$1.6 million, with a median of -$794000.0 recorded in 2022.
- Year-over-year, Cash from Investing Activities jumped 92.45% in 2024 and sank 6633.71% in 2025.
- Tracing OCUL's Cash from Investing Activities over 5 years: stood at -$2.2 million in 2022, then surged by 78.65% to -$459000.0 in 2023, then soared by 55.99% to -$202000.0 in 2024, then plunged by 1305.45% to -$2.8 million in 2025, then slumped by 64.21% to -$4.7 million in 2026.
- The last three Cash from Investing Activities figures came in at -$4.7 million (Q1 2026), -$2.8 million (Q4 2025), and -$6.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | -4.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.66 Mn |
| Mar 31, 2026 | -4.66 Mn |
| Dec 31, 2025 | -2.84 Mn |
| Dec 31, 2025 | -2.84 Mn |
| Sep 30, 2025 | -5.99 Mn |
| Sep 30, 2025 | -5.99 Mn |
| Jun 30, 2025 | -1.12 Mn |
| Jun 30, 2025 | -1.12 Mn |
| Mar 31, 2025 | -1.93 Mn |
| Mar 31, 2025 | -1.93 Mn |
| Dec 31, 2024 | -202,000.00 |
| Dec 31, 2024 | -202,000.00 |
| Sep 30, 2024 | -89,000.00 |
| Sep 30, 2024 | -89,000.00 |
| Jun 30, 2024 | -742,000.00 |
| Jun 30, 2024 | -742,000.00 |
| Mar 31, 2024 | -255,000.00 |
| Mar 31, 2024 | -255,000.00 |
| Dec 31, 2023 | -459,000.00 |
| Dec 31, 2023 | -459,000.00 |
| Sep 30, 2023 | -259,000.00 |
| Sep 30, 2023 | -259,000.00 |
| Jun 30, 2023 | -1.99 Mn |
| Jun 30, 2023 | -1.99 Mn |
| Mar 31, 2023 | -3.38 Mn |
| Mar 31, 2023 | -3.38 Mn |
| Dec 31, 2022 | -2.15 Mn |
| Dec 31, 2022 | -2.15 Mn |
| Sep 30, 2022 | -794,000.00 |
| Sep 30, 2022 | -794,000.00 |
| Jun 30, 2022 | -495,000.00 |
| Jun 30, 2022 | -495,000.00 |
| Mar 31, 2022 | -276,000.00 |
| Mar 31, 2022 | -276,000.00 |
| Dec 31, 2021 | -631,000.00 |
| Dec 31, 2021 | -631,000.00 |
| Sep 30, 2021 | -276,000.00 |
| Sep 30, 2021 | -276,000.00 |
| Jun 30, 2021 | -129,000.00 |
| Jun 30, 2021 | -129,000.00 |
| Mar 31, 2021 | -158,000.00 |
| Mar 31, 2021 | -158,000.00 |
| Dec 31, 2020 | -253,000.00 |
| Dec 31, 2020 | -253,000.00 |
| Sep 30, 2020 | -214,000.00 |
| Sep 30, 2020 | -214,000.00 |
| Jun 30, 2020 | -125,000.00 |
| Jun 30, 2020 | -125,000.00 |
| Mar 31, 2020 | -249,000.00 |
| Mar 31, 2020 | -249,000.00 |
| Dec 31, 2019 | -601,000.00 |
| Dec 31, 2019 | -601,000.00 |
| Sep 30, 2019 | -419,000.00 |
| Sep 30, 2019 | -419,000.00 |
| Jun 30, 2019 | -493,000.00 |
| Jun 30, 2019 | -493,000.00 |
| Mar 31, 2019 | -725,000.00 |
| Mar 31, 2019 | -725,000.00 |
| Dec 31, 2018 | -479,000.00 |
| Dec 31, 2018 | -479,000.00 |
| Sep 30, 2018 | -473,000.00 |
| Sep 30, 2018 | -473,000.00 |
| Jun 30, 2018 | -556,000.00 |
| Jun 30, 2018 | -556,000.00 |
| Mar 31, 2018 | -381,000.00 |
| Mar 31, 2018 | -381,000.00 |
| Dec 31, 2017 | -564,000.00 |
| Dec 31, 2017 | -564,000.00 |
| Sep 30, 2017 | 969,000.00 |
| Sep 30, 2017 | 969,000.00 |
| Jun 30, 2017 | 18.70 Mn |
| Jun 30, 2017 | 18.70 Mn |
| Mar 31, 2017 | 7.85 Mn |
| Mar 31, 2017 | 7.85 Mn |
| Dec 31, 2016 | -10.88 Mn |
| Dec 31, 2016 | -10.88 Mn |
| Sep 30, 2016 | 11.32 Mn |
| Sep 30, 2016 | 11.32 Mn |
| Jun 30, 2016 | 11.76 Mn |
| Jun 30, 2016 | 11.76 Mn |
| Mar 31, 2016 | 24.87 Mn |
| Mar 31, 2016 | 24.87 Mn |
| Dec 31, 2015 | -2.09 Mn |
| Dec 31, 2015 | -2.09 Mn |
| Sep 30, 2015 | -27.59 Mn |
| Sep 30, 2015 | -27.59 Mn |
| Jun 30, 2015 | 8.96 Mn |
| Jun 30, 2015 | 8.96 Mn |
| Mar 31, 2015 | -17.85 Mn |
| Mar 31, 2015 | -17.85 Mn |
| Dec 31, 2014 | -37.77 Mn |
| Dec 31, 2014 | -37.77 Mn |
| Sep 30, 2014 | -274,000.00 |
| Sep 30, 2014 | -274,000.00 |
| Jun 30, 2014 | -248,000.00 |
| Jun 30, 2014 | -248,000.00 |
| Mar 31, 2014 | -297,000.00 |
| Mar 31, 2014 | -297,000.00 |
| Dec 31, 2013 | -206,000.00 |
| Dec 31, 2013 | -206,000.00 |
| Sep 30, 2013 | -109,000.00 |
| Sep 30, 2013 | -109,000.00 |